KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG VÀ CẬN LÂM SÀNG CỦA BỆNH GAN NHIỄM MỠ KHÔNG DO RƯỢU Ở BỆNH NHÂN CÓ TĂNG NỒNG ĐỘ AXIT URIC HUYẾT THANH

Tiến Đào Đức; Hiều Trần Văn

doi:10.59354/ydth175.2025.364

Keywords:

Non-alcoholic fatty liver disease, hyperuricemia

Abstract

Objectives: To determine the clinical and subclinical characteristics of nonalcoholic fatty liver disease (NAFLD) in patients with hyperuricemia

Materials and methods: A cross-sectional study was conducted on 234 patients with hyperuricemia who presented for examination and treatment at Military Hospital 175 from May 2023 to May 2024. NAFLD was diagnosed using FibroScan, and the clinical and paraclinical characteristics of this patient group were evaluated.

Results: The prevalence of NAFLD among patients with hyperuricemia was 55.13% with a mean CAP of 281.05 ± 31.99 dB/m (234 - 356 dB/m). The mean age was 47.85 ± 12.95 years, with a male-to-female ratio of 4.38:1. A majority of patients (82.17%) were overweight or obese, and 86.82% were asymptomatic. Laboratory findings revealed a median serum uric acid level of 482.0 µmol/L (IQR: 450.0–530.45 µmol/L), with high prevalence rates of dyslipidemia—elevated LDL, triglyceride, and cholesterol were observed in 63.57%, 64.34%, and 71.32% of patients, respectively. Additionally, 62.79% of patients exhibited elevated GGT levels.

Conclusion: NAFLD is relatively common in patients with hyperuricemia (55.13%), mainly occurring in middle-aged men who are overweight or obese and often accompanied by dyslipidemia. The majority of these cases present without clinical symptoms

References

Riazi K., Azhari H., Charette J. H., et al. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 7(9): 851-861.

Oral A., Sahin T., Turker F., et al. (2019). Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients. Medicina (Kaunas), 55(9).

Kasper P., Martin A., Lang S., et al. (2021). NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol, 110(7): 921-937.

Rahimi-Sakak F., Maroofi M., Rahmani J., et al. (2019). Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord, 19(1): 218.

Karlas T., Petroff D., Garnov N., et al. (2014). Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One, 9(3): e91987.

Cai W., Song J.-m., Zhang B., et al. (2014). The Prevalence of Nonalcoholic Fatty Liver Disease and Relationship with Serum Uric Acid Level in Uyghur Population. The Scientific World Journal, 2014: 393628

Carulli L., Lonardo A., Lombardini S., et al. (2006). Gender, fatty liver and GGT. Hepatology, 44(1): 278-279. 8. Ahmed M. (2015). Non-alcoholic fatty liver disease in 2015. World J Hepatol, 7(11): 1450-1459.

Assy N., Kaita K., Mymin D., et al. (2000). Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci, 45(10): 1929-1934.

Méndez-Sánchez N., Cerda-Reyes E., Higuera-de-la-Tijera F., et al. (2020). Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Res, 9: 56.

Witters P., Freson K., Verslype C., et al. (2008). Blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther, 27(11): 1017-1029.

Đỗ Minh Quân, Trần Thị Khánh Tường. (2024). Tỷ lệ bệnh gan nhiễm mỡ liên quan chuyển hóa ở bệnh nhân đái tháo đường típ 2. Tạp chí Y học Việt Nam, 534(1)